BC
APLS

Bridgefront Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Bridgefront Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,326
Closed -$285K – 524
2025
Q4 		$285K Buy
+11,326
New +$266K 0.07% 382
2025
Q2 		– Sell
-29,070
Closed -$636K – 596
2025
Q1 		$636K Buy
+29,070
New +$803K 0.18% 186
2023
Q4 		– Sell
-6,802
Closed -$259K – 368
2023
Q3 		$259K Buy
6,802
+4,175
+159% +$183K 0.18% 249
2023
Q2 		$239K Buy
+2,627
New +$227K 0.13% 333
2021
Q3 		– Sell
-3,390
Closed -$214K – 326
2021
Q2 		$214K Sell
3,390
-1,289
-28% -$66.5K 0.08% 484
2021
Q1 		$201K Buy
+4,679
New +$221K 0.06% 587

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bridgefront Capital's APLS Position: Q1 2026 in Review

Bridgefront Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 11,326 shares — an estimated $285K sold.

Bridgefront Capital first reported a position in APLS in Q1 2021 and held it in 6 quarters. The position peaked at $636K in Q1 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Bridgefront Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bridgefront Capital sold 11,326 Apellis Pharmaceuticals shares in Q1 2026, an estimated $285K.
  • Bridgefront Capital first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Bridgefront Capital's Apellis Pharmaceuticals position peaked at $636K in Q1 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.